Law Extends Federal Support for ALS Treatment Access

Adults with ALS and their families gain five more years of programs that expand access to investigational therapies.

Updated on Nov. 3, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a glass vial with a coral cap on a cream tray, linked by a steel conduit to a distant doorway, evoking a treatment path from research toward patients.
President Trump signed the ACT for ALS Reauthorization Act into law on November 3, 2026, extending five years of programs that expand access to investigational ALS therapies. AI Illustration. Upload story photo >

President Trump signed the ACT for ALS Reauthorization Act into law on November 3, 2026, extending programs that expand access to investigational ALS therapies for five years. The bipartisan legislation was co-championed by the Muscular Dystrophy Association alongside advocates, researchers, clinicians, industry leaders, and families.

Why it matters

The reauthorization preserves federal initiatives that accelerate discovery, development, and delivery of ALS treatments, which matters for people living with a disease that currently has no cure. It also strengthens research infrastructure for ALS and other rare neurodegenerative diseases, a goal that has been difficult to sustain across short funding cycles.

The reauthorization extends a federal law first enacted in 2021 for a five-year period, rather than presenting a new clinical study. The 5 to 10 percent familial share of ALS cases is the figure reported, and the expected acceleration of therapy development remains a projection.

The players

Muscular Dystrophy Association

The Muscular Dystrophy Association is a nonprofit that operates a nationwide network of MDA/ALS Care Centers and has spent seven decades on ALS research and neuromuscular disease care.

Sharon Hesterlee

Sharon Hesterlee is President and CEO of the Muscular Dystrophy Association, which co-led advocacy for the legislation.

Paul Melmeyer

Paul Melmeyer is Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association.

The details

The law extends programs that expand access to investigational therapies, meaning treatments still being tested that patients can sometimes receive before full approval. It also supports clinical trial approaches intended to make studies more innovative and efficient. Together these provisions aim to shorten the path from laboratory research to treatments reaching people with ALS.

Timeline

  1. The ACT for ALS Act was first enacted in 2021.

  2. President Trump signed the ACT for ALS Reauthorization Act into law on November 3, 2026.

Health Landscape

The reauthorization continues the approach set by the 2021 ACT for ALS Act, which targets treatment access and research infrastructure for ALS. It also reflects continued federal attention to rare neurodegenerative diseases, a category where sustained programs are often needed because patient populations are small.

If you or a family member has been diagnosed with ALS, the reauthorization may expand access to investigational therapies over the coming years. Because military veterans and firefighters have nearly double the general population's chance of developing ALS, those groups may find it especially worth discussing risk and clinical trial options with their physicians.

The takeaway

The reauthorization gives ALS research and treatment-access programs five more years of federal support, but there is still no cure. If ALS is a concern for you or someone you know, bring it up with a neurologist, who can explain whether clinical trials may be an option.

Further reading

For broader context on neurodegenerative disease research, explore the Alzheimer’s section.

Source note: This article includes information reported by The Manila times.